Mi SciELO
Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Citado por Google
- Similares en SciELO
- Similares en Google
Compartir
Archivos de la Sociedad Española de Oftalmología
versión impresa ISSN 0365-6691
Resumen
RAMIREZ-SORIA, M.P.; ESPANA-GREGORI, E.; AVINO-MARTINEZ, J. y PASTOR-PASCUAL, F.. Blepharitis related to Cetuximab treatment in an advanced colorectal cancer patient. Arch Soc Esp Oftalmol [online]. 2008, vol.83, n.11, pp.665-668. ISSN 0365-6691.
Case report: A 52-year-old woman with advanced colorectal cancer was referred to us for treatment of Cetuximab-related ocular side-effects. Discussion: Cetuximab is a monoclonal antibody that specifically blocks epidermal growth factor receptor activity. It has recently been approved to treat some tumors such as metastatic colorectal cancer and some ORL cancers. Tolerance to it seems to be better than that to the classic chemotherapeutic agents. However it has several side-effects. Cetuximab-related eyelid toxicity has been recently described, though the pathogenesis has not yet been clearly established.
Palabras clave : Colorectal cancer; monoclonal antibodies; epidermal growth factor receptor; blepharitis.